Clinical Trials in Boston

Showing 3381-3400 of 15,299 trials

Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea

NCT04801771

This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.

Down SyndromeObstructive Sleep Apnea

Inspire Medical Systems, Inc.57 participantsStarted Jun 2021

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Cincinnati, Ohio, United States +5 more locations

RECRUITINGPhase 2< 1 mile

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

NCT04079179

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

Langerhan's Cell HistiocytosisJuvenile XanthogranulomaErdheim-Chester Disease+4 more

Carl Allen90 participantsStarted Apr 2021

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Orange, California, United States +9 more locations

Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Find Trials by Condition in Boston

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

HLA Demographics Study in Adults With Type 1 Diabetes

Vertical Soft Tissue Augmentation With CTG vs ADM

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Boston Birth Cohort Study

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Promising ROd-cone DYstrophy Gene therapY

Mechanisms of Open and Hidden Placebo in Stroke Recovery

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

BlueWind RENOVA iStim™ System for the Treatment of OAB

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Global Trial in APG2575 for Patients With CLL/SLL